Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Dare Bioscience, Inc.
DARE · SEC Filings
website
23
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infe...
Price
0.68
Market Cap
13.37 M
Float
19.57 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about DARE
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Dare Bioscience, Inc.
DARE · SEC Filings
19.57 M
Float
0.68
Price
13.37 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
News
TYPE
HEADLINE
FILED AT
8-K
Daré Bioscience Receives Nasdaq Minimum Bid Price Deficiency Notice
Oct 2, 2026
8-K
Daré Bioscience Furnishes Corporate Presentation for October 2026 Meetings
Oct 1, 2026
8-K
Daré Bioscience Amends By-Laws to Reduce Stockholder Meeting Quorum Requirement
Sep 11, 2026
8-K
Daré Bioscience Furnishes Corporate Presentation for September 2026 Meetings
Sep 9, 2026
8-K
Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement
Aug 17, 2026
8-K
Daré Bioscience Reports Second Quarter 2026 Results and Advances Multi-Product Women’s Health Commercial Strategy
Aug 13, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B3
SHARE RESALE REGISTRATION | Shares: 8,934,345
Sep 4, 2026
253G2
Form 253G2 -
Aug 19, 2026
424B5
REGISTERED OFFERING
Aug 17, 2026
253G2
Form 253G2 -
Jul 17, 2026
253G2
Form 253G2 -
May 14, 2026
253G2
Form 253G2 -
Mar 27, 2026
Registrations
TYPE
HEADLINE
FILED AT
S-1
SHARE RESALE REGISTRATION
Aug 26, 2026
D
Form D - Notice of Exempt Offering of Securities - Item 06b
Aug 19, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Jun 23, 2026
1-A POS
OFFERING - Other
Mar 27, 2026
1-A/A
Form 1-A/A - Offering Statement [Regulation A]: [Amend]
Dec 29, 2025
1-A
Form 1-A - Offering Statement [Regulation A]
Nov 25, 2025
Proxies
TYPE
HEADLINE
FILED AT
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G
Lind Global Fund III LP (Filed by)
Aug 28, 2026
SCHEDULE 13G
L1 Capital Global Opportunities Master Fund, Ltd. (Filed by)
Aug 24, 2026
4
Grossman Jessica D. (Reporting)
Jul 2, 2026
4
Kelley Susan L. (Reporting)
Jul 2, 2026
4
Matz Gregory W (Reporting)
Jul 2, 2026
4
RASTETTER WILLIAM H (Reporting)
Jul 2, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Sep 4, 2026
QUALIF
Form QUALIF - Notice of Qualification [Regulation A]
Apr 2, 2026
QUALIF
Form QUALIF - Notice of Qualification [Regulation A]
Jan 6, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
Nov 27, 2024
CORRESP
Form CORRESP - Correspondence
Nov 22, 2024
LETTER
Form UPLOAD - SEC-generated letter
Nov 19, 2024
